Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia

References

• Dohner H, Estey EH, Amadori S, . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Acute Myeloid Leukemia, version 2.2011. Available from: www.nccn.org
   Google Scholar
• Camera A, Rinaldi CR, Palmieri S, . Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Ann Hematol 2009;88:151–158.
   PubMed Web of Science ®Google Scholar
• Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004:98–117.
   Google Scholar
• Shih LY, Huang CF, Wu JH, . Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clin Cancer Res 2004;10:1326–1332.
   PubMed Web of Science ®Google Scholar
• Hu S, Niu H, Minkin P, . Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 2008;7:1110–1120.
   PubMed Web of Science ®Google Scholar
• Zhou J, Goh B-C, Albert D, . ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol 2009;2:33.
   PubMed Web of Science ®Google Scholar
• Kim KT, Baird K, Ahn JY, . Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005;105:1759–1767.
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002;1:413–415.
   PubMed Web of Science ®Google Scholar
• Shih LY, Huang CF, Wu JH, . Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002;100:2387–2392.
   PubMed Web of Science ®Google Scholar
• Metzelder S, Wang Y, Wollmer E, . Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567–6571.
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett AK, Littlewood T, . A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262–3270.
   PubMed Web of Science ®Google Scholar
• Wiernik PH. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol 2010;8:429–444.
   PubMedGoogle Scholar
• Shankar DB, Li J, Tapang P, . ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007;109: 3400–3408.
   PubMed Web of Science ®Google Scholar
• Albert DH, Tapang P, Magoc TJ, . Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006;5:995–1006.
   PubMed Web of Science ®Google Scholar
• Zhou J, Pan M, Xie Z, . Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 2008;22:138–146.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. Available from: http://ctep.cancer.gov
   Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Sato T, Yang X, Knapper S, . FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011;117:3286–3293.
   PubMed Web of Science ®Google Scholar
• Roukos DH, Tzakos A, Zografos G. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 2009;9:1413–1416.
   PubMed Web of Science ®Google Scholar
• Wong C-I, Koh T-S, Soo R, . Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009;27:4718–4726.
   PubMed Web of Science ®Google Scholar
• Kumar R, Crouthamel M-C, Rominger D, . Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101:1717–1723.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes JE, Jones D, . Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856–1862.
   PubMed Web of Science ®Google Scholar
• Crump M, Hedley D, Kamel-Reid S, . A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 2010;51:252–260.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Kantarjian H, Ravandi F, . Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011;96:62–68.
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, DeAngelo DJ, . Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339–4345.
   PubMed Web of Science ®Google Scholar
• Levis M, Ravandi F, Wang ES, . Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011;117:3294–3301.
   PubMed Web of Science ®Google Scholar
• Pratz KW, Cho E, Levis MJ, . A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010;24:1437–1444.
   PubMed Web of Science ®Google Scholar
• Pratz KW, Cortes J, Roboz GJ, . A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009;113:3938–3946.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, ., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. >4th ed. Lyon, France: IARC; 2008.
   Google Scholar